- Allied and HAVN Life Sciences (HAVN) have signed an agreement to produce Psilonex RX for the largest known psilocybin patient cohort in the world
- Psilonex RX is Allied’s proprietary formulation of psilocybin
- The 300-person cohort includes veterans, police and fire and ambulance personnel struggling with post-trauma symptoms
- HAVN will produce bottles of Psilonex RX capsules for the patients
- Allied views the project as essential to further the foundations of psychedelics research
- Allied’s mission is to address today’s medical issues by researching, creating and producing targeted health solutions
- HAVN Life Sciences is focused on extracting psychoactive compounds and developing natural healthcare products and mental health treatments
- HAVN Life Sciences (HAVN) is down by 8.33 per cent and is currently trading at $0.55 per share
Allied and HAVN Life Sciences (HAVN) have signed an agreement to produce Psilonex RX for Allied’s patient cohort.
Psilonex RX is Allied’s proprietary formulation of psilocybin, cordyceps, lions mane, vitamin B and other ingredients.
Allied has access to a cohort of over 300 veterans, police and fire and ambulance personnel struggling with post-trauma symptoms and requesting Psilonex RX. The company will care for the cohort under physician supervision and seek Section 56 special access exemptions to administer Psilonex RX products.
HAVN will produce bottles of Psilonex RX capsules ready to be dispensed in accordance with the Office of Controlled Substances of Canada.
Allied plans to gather data from the project to further provide a foundation for future research and product development.
Calum Hughes, CEO of Allied Corp., commented,
“We have the patient cohort, the physician oversight, the holistic nutritionists and psilocybin experts, the pharmacist scientists and physician research team all in place. The last piece of the puzzle was the manufacturer and supplier. With this now in place, we are ready to embark on providing legal psilocybin products to the largest patient cohort that we know of in the world. The significance that this represents to the global pharmaceutical markets of depression and anxiety is very exciting to say the least. Allied is at the forefront of this industry.”
Allied’s mission is to address today’s medical issues by researching, creating and producing targeted health solutions.
HAVN Life Sciences is focused on extracting psychoactive compounds and developing natural healthcare products and mental health treatments.
HAVN Life Sciences (HAVN) is down by 8.33 per cent and is currently trading at $0.55 per share as of 10:21 am ET.
